Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATFurniture, Fixtures and OtherLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShort-Term Debt repayments
Ratios

Plus Therapeutics (PSTV) Receivables - Other (2016 - 2025)

Plus Therapeutics (PSTV) has disclosed Receivables - Other for 13 consecutive years, with $1.0 million as the latest value for Q2 2025.

  • On a quarterly basis, Receivables - Other changed N/A to $1.0 million in Q2 2025 year-over-year; TTM through Jun 2025 was $1.0 million, a N/A change, with the full-year FY2024 number at $571000.0, changed N/A from a year prior.
  • Receivables - Other was $1.0 million for Q2 2025 at Plus Therapeutics, up from $571000.0 in the prior quarter.
  • In the past five years, Receivables - Other ranged from a high of $1.0 million in Q2 2025 to a low of $73000.0 in Q3 2022.
  • A 4-year average of $494800.0 and a median of $571000.0 in 2024 define the central range for Receivables - Other.
  • Biggest YoY gain for Receivables - Other was 24.66% in 2023; the steepest drop was 24.66% in 2023.
  • Plus Therapeutics' Receivables - Other stood at $73000.0 in 2022, then rose by 24.66% to $91000.0 in 2023, then surged by 527.47% to $571000.0 in 2024, then skyrocketed by 78.81% to $1.0 million in 2025.
  • Per Business Quant, the three most recent readings for PSTV's Receivables - Other are $1.0 million (Q2 2025), $571000.0 (Q4 2024), and $91000.0 (Q3 2023).